Newcastle University

Publications

Year: 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1984 1983 1980 1979

• Griffin, R. J., Barlow, H. C., Curtin, N. J., Calvert, A. H., Golding, B. T., Newell, D. R., Smith, P. G. 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP). Clinical Cancer Research 1999, 5(Supplement 1), 3843 no. 564.
• Lu, X., Errington, J., Lunec, J., Chen, V. J., Curtin, N. J., Boddy, A. V., Newell, D. R. GARFT inhibitor LY309887 cytotoxicity correlates with ATP depletion but not with p53 status in human tumour cell lines. In: BRITISH JOURNAL OF CANCER. 1999.
• Jodrell, D., Bowman, A., Rye, R., Byrne, B., Boddy, A. V., Rafi, I., Taylor, G., Johnston, A., Clendeninn, N. A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq® (nolatrexed dihydrochloride) given by 10-day oral administration. British Journal of Cancer 1999, 79(5/6), 915-920.
• Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, Rees JKH, Stevens RF, Walker H. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. British Journal of Haematology 1999, 107(1), 69-79.
• Cole M. Adversary politics and proportional representation. Political Quarterly 1999, 70(2), 166-174.
• Newell, D. R., Arris, C. E., Boyle, F. T., Calvert, A. H., Curtin, N. J., Dewsbury, P., Endicott, J. A., Garman, E. F., Gibson, A. E., Golding, B. T., Griffin, R. J., Johnson, L. N., Lawrie, A., Noble, M. E. M., Sausville, E. A., Schultz, R. Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Clinical Cancer Research 1999, 5(Supplement 1), S3755 no. 124.
• Skamnaki VT, Owen DJ, Noble MEM, Lowe ED, Lowe G, Oikonomakos NG, Johnson LN. Catalytic Mechanism of Phosphorylase Kinase Probed by Mutational Studies. Biochemistry 1999, 38(4), 14718-14730.
• Noble MEM, Endicott JA. Chemical inhibitors of cyclin-dependent kinases: Insights into design from X-ray crystallographic studies. In: Pharmacology & Therapeutics: 1st International Conference on Inhibitors of Protein Kinases (IPK). 1999, Warsaw, Poland: Elsevier Inc.
• Gribble S, Sinclair PB, Grace C, Green AR, Nacheva EP. Comparative analysis of G-banding, chromosome painting, locus specific FISH and CGH in chronic myeloid leukemia blast chrisis. Cancer Genetics and Cytogenetics 1999, 111(1), 7-17.
• Endicott JA, Noble MEM, Tucker JA. Cyclin-dependent kinases: inhibition and substrate recognition. Current Opinion in Structural Biology 1999, 9(6), 738-744.
• Yule, S. M., Price, L., Cole, M., Pearson, A. D. J., Boddy, A. V. Cyclophosphamide metabolism in children with Fanconi's anaemia. Bone Marrow Transplantation 1999, 24(2), 123-128.
• Boulton SJ, Kyle S, Durkacz BW. Cytotoxic mechanism of the protein kinase inhibitor wortmannin in ionising radiation and etoposide treated cells. British Journal of Cancer 1999, 80(supplement 2), 44 P64.
• Hennequin LF, Thomas AP, Johnstone C, Stokes ESE, Plé PA, Lohmann JM, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert-vanderBrempt C. Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry 1999, 42(26), 5369-5389.
• Duerr EM, Gimm O, Neuberg DS, Kum JB, Clifford SC, Toledo SP, Maher ER, Dahia PL, Eng C. Differences in allelic distribution of two polymorphisms in the VHL-associated gene CUL2 in pheochromocytoma patients without somatic CUL2 mutations. Journal of Clinical Endocrinology and Metabolism 1999, 84(9), 3207-3211.
• Crosier M, Scott D, Wilson RG, Griffiths CDM, May FEB, Westley BR. Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clinical Cancer Research 1999, 5(10), 2682-2688.
• Lovat, P.E., Annicchiarico-Petruzzelli, M., Corazzari, M., Dobson, M., Malcolm, A.J., Pearson, A.D.J., Melino, G., Redfern, C.P.F. Differential effects of retinoic acid isomers on the expression of nuclear receptor co-regulators in neuroblastoma. FEBS Letters 1999, 445(2-3), 415-419.
• Curtin, N.J., Turner, D.P. Dipyridamole-mediated reversal of multidrug resistance in MRP over- expressing human lung carcinoma cells in vitro. European Journal of Cancer 1999, 35(6), 1020-1026.
• Andersson ML, Lindeskog M, Medstrand P, Westley BR, May FEB, Blomberg J. Diversity of human endogenous retrovirus class II-like sequences. Journal of General Virology 1999, 80(1), 255-260.
• Brown NR, Noble MEM, Lawrie AM, Morris MC, Tunnah P, Divita G, Johnson LN, Endicott JA. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. Journal of Biological Chemistry 1999, 274(13), 8746-8756.
• Rutter MR, McComb JM, Kesteven P, Marshall SM, Jackson G. Endothelial dysfunction, disordered coagulation and fibrinolysis in patients with type 2 diabetes and microalbuminuria. In: Forty-first Annual Meeting of the American Society of Hematology. 1999, Oakland, California, USA: American Society of Hematology.
• Major GN, Notarianni GB, Ross SJ, Case MC, Brannigan JA, Roper DI, Potter PM, Brent TP, Moody PCE. Evidence for autoproteolysis of substrate-inactivated O-6-methylguanine-DNA methyltransferase following DNA repair. In: British Journal of Cancer. 1999, Nature Publishing Group.
• Karat D, Brotherick I, Shenton BK, Scott D, Raimes SA, Griffin SM. Expression of oestrogen and progesterone receptors in gastric cancer: a flow cytometric study. British Journal of Cancer 1999, 80(8), 1271-1274.
• Harrison CJ, Ross F, Radford-Weiss I, le Guyader G, Rack K, Vekemans M, Macintyre EM. Fluorescence In Situ Hybridization Analysis of Masked (8;21)(q22;q22) Translocations. Cancer Genetics & Cytogenetics 1999, 112(1), 15-20.
• Clifford SC, Walsh S, Hewson K, Green EK, Brinke A, Green PM, Gianelli F, Eng C, Maher ER. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development. Genes Chromosomes, & Cancer 1999, 26(1), 20-28.
• Bailey, S., Hall, A.G., Pearson, A.D.J., Reid. M., Redfern, C.P.F. Glucocorticoid resistance and the AP-1 transcription factor in leukaemia. Advances in Experimental Medicine and Biology 1999, 457, 615-619.
• Arris CE, Boyle FT, Calvert AH, Curtin NJ, Dewsbury PJ, Endicott JA, Gibson AE, Golding BT, Grant S, Griffin RJ, Johnson, L. N., Noble, M. E. M., Newell, D. R., Sausville, E., Schultz, R. In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors. British Journal of Cancer 1999, 80(Supplement 2), 11 no. 110.
• Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 1999, 93(8), 2671-2678.
• Hoessel R, Leclerc S, Endicott JA, Noble MEM, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang WC, Eisenbrand G, Meijer L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature cell biology 1999, 1(1), 60-67.
• Boulton, S., Kyle, S, Durkacz, B.W. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 1999, 20(2), 199-203.
• Rajentheran R, McLean NR, Kelly CG, Reed MF, Nolan A. Malignant transformation of oral lichen planus. European Journal of Surgical Oncology 1999, 25(5), 520-523.
• Errington F, Willmore E, Tilby MJ, Li L, Li G, Li W, Baguley B, Austin CA. Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: Analysis of cytotoxicity and cleavable complex formation. Molecular Pharmacology 1999, 56(6), 1309-1316.
• Smith, P. G., Barlow, H. C., Loughlin, P., Huang, B., Bowman, K. J., Calvert, A. H., Curtin, N. J., Golding, B. T., Griffin, R. J., Newell, D. R. Novel dipyridamole analogues potentiate the in vitro activity of MTA (LY231514) in the presence of alpha(1)-acid glycoprotein. British Journal of Cancer 1999, 80(Supplement 2), 49 no. 82.
• Stiller, C. A., Benjamin, S., Cartwright, R. A., Clough, J. V., Gorst, D. W., Kroll, M. E., Ross, J. R. Y., Wheatley, K., Whittaker, J. A., Taylor, P. R. A., Proctor, S. J. Patterns of care and survival for adolescents and young adults with acute leukaemia - a population-based study. British Journal of Cancer 1999, 79(3-4), 658-665.
• Hayes N, Wayman J, Wadehra V, Scott DJ, Raimes SA, Griffin SM. Peritoneal cytology in the surgical evaluation of gastric carcinoma. British Journal of Cancer 1999, 79(3-4), 520-524.
• Hughes, A. N., Rafi, I., Griffin, M. J., Calvert, A. H., Newell, D. R., Calvete, J., Johnston, A., Clendeninn, N., Boddy, A. V. Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. Clinical Cancer Research 1999, 5(1), 111-118.
• Curtin, N. J., Kyle, S., Wang, L. Z., Durkacz, B. W., White, A. J., Srinivasan, S., Griffin, R. J., Golding, B. T., Newell, D. R., Calvert, A. H., Maegley, K., Hostomsky, Z. Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors. Clinical Cancer Research 1999, 5(Supplement 1), S3834 no. 520.
• Curtin, N.J., Bowman, K., Turner, R., Huang, B., Loughlin, P., Calvert, A.H., Golding, B.T., Griffin, R.J., Newell, D.R. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α1-acid glycoprotein binding. British Journal of Cancer 1999, 80(11), 1738-1746.
• Calabrese CR, Thomas HD, Batey MA, Boritzki T, Zhang K, White AW, Curtin NJ, Griffin RJ, Golding BT, Hostomsky Z, Calvert AH, Newell DR. Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase. Clinical Cancer Research 1999, 5(Suppl. 1), S3839-S3839.
• Chu C, Sheridan E, Turner G, Robson F, Mason G, Thornton J, Burn J. Prenatal testing for cancer predisposition syndromes. Journal of Medical Genetics 1999, 36, S35-S35.
• Smith, P.G., Marshman, E., Calvert, A., Newell, D.R., Curtin, N.J. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines. Seminars in Oncology 1999, 26(2), 63-67.
• Westley BR, May FEB. Prognostic value of cathepsin D in breast cancer. British Journal of Cancer 1999, 79(2), 189-190.
• Golding BT, Mitchinson A, Clegg W, Elsegood MRJ, Griffin RJ. Protecting-group strategies for the synthesis of N4-substituted, and N1,N8-disubstituted spermidines, exemplified by hirudonine. Journal of the Chemical Society - Perkin Transactions 1 1999, (3), 349-356.
• Cerny, T., Leyvraz, S., von Briel, T., Kupfer, A., Schaad, R., Schmitz, S. F. H., Honegger, P., Sessa, C., Brunner, J., Boddy, A. V. Saturable metabolism of continuous high-dose ifosfamide with Mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients. Annals of Oncology 1999, 10(9), 1087-1094.
• Donaghue C, Westley BR, May FEB. Selective promoter usage of the human estrogen receptor-alpha gene and its regulation by estrogen. Molecular Endocrinology 1999, 13(11), 1934-1950.
• Johnson LN, Noble MEM, Barford D, Brown N, Endicott JA, Lawrie A, Owen DJ. Signal transduction proteins: Structural basis of control by phosphorylation. Journal of the Chemical Society of Pakistan 1999, 21(3), 185-201.
• Edmondson R. Staff changes will have affected ventouse rates. British Medical Journal 1999, 318(7191), 1144-1144.
• Kitching MS, Clegg W, Elsegood MRJ, Griffin RJ, Golding BT. Synthesis of 3-alkoxy- and 3-alkylamino-2-alkyl-3-arylisoindolinones. Synlett 1999, 997-999.
• Plummer CJ, Parry G, McComb J. Tachy-brady syndrome six years after cardiac transplantation. HeartWeb 1999, 4(10), U19-U23.
• Yule, S. M., Walker, D., Cole, M., McSorley, L., Cholerton, S., Daly, A. K., Pearson, A. D. J., Boddy, A. V. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metabolism and Disposition 1999, 27(3), 417-421.
• Coulthard, S., Minto, C.L.J., Matheson, N., Hall, A.G. The effect of thiopurine methyltransferase activity on the survival in patients with acute leukaemia. British Journal of Cancer 1999, 80(1/2), 81-81.
• Brown NR, Noble MEM, Endicott JA, Johnson LN. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nature Cell Biology 1999, 1(7), 438-443.
• Calnan DP, Westley BR, May FEB, Floyd DN, Marchbank T, Playford RJ. The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. Journal of Pathology 1999, 188(3), 312-317.
• Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399(6733), 271-275.
• Brady, M. E., Ozanne, D. M., Gaughan, L., Waite, I. S., Cook, S., Neal, D. E., Robson, C. N. Tip60 is a nuclear hormone receptor coactivator. Journal of Biological Chemistry 1999, 274(25), 17599-17604.
• Dickinson AM, Hromadníková I, Sviland L, Jackson GH, Taylor PRA, Vavrinec J, Sedlacek P, Cermáková M, Starý J, Vitek A, Sajdová J, Proctor SJ. Use of a skin explant model for predicting GVHD in HLA-matched bone marrow transplants - effect of GVHD prophylaxis. Bone Marrow Transplantation 1999, 24(8), 857-863.
• Walker SR, Heer R, MacSweeney ST. Vascular surgical society of great britain and ireland: prospective randomized double-blind placebo-controlled crossover study to assess the effect of sublingual glyceryl trinitrate in patients with intermittent claudication. British Journal of Surgery 1999, 86(5), 694.